Cargando…

Reply: Roll out of bedaquiline without drug susceptibility testing leads to emergence of bedaquiline-resistance in high burden countries with tuberculosis - Danger of losing a novel drug

Detalles Bibliográficos
Autor principal:	Jain, Nirmal Kumar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9390310/ https://www.ncbi.nlm.nih.gov/pubmed/35848680 http://dx.doi.org/10.4103/lungindia.lungindia_31_22

Ejemplares similares

Emergence of bedaquiline resistance in a high tuberculosis burden country
por: Chesov, Elena, et al.
Publicado: (2022)

Maleate salts of bedaquiline
por: Zeller, Matthias, et al.
Publicado: (2021)

Coadministration of bedaquiline and pyrifazimine reduce exposure to toxic metabolite N-desmethyl bedaquiline
por: Ding, Yangming, et al.
Publicado: (2023)

Bedaquiline: A novel drug to combat multiple drug-resistant tuberculosis
por: Goel, Divya
Publicado: (2014)

Bedaquiline Phenotypic and Genotypic Susceptibility Testing, Work in Progress!
por: Tiberi, Simon, et al.
Publicado: (2018)

New drugs to treat multidrug-resistant tuberculosis: the case for bedaquiline
por: Leibert, Eric, et al.
Publicado: (2014)

Bedaquiline: First FDA-approved tuberculosis drug in 40 years
por: Mahajan, Rajiv
Publicado: (2013)

Bedaquiline and Linezolid for Extensively Drug-Resistant Tuberculosis in Pregnant Woman
por: Jaspard, Marie, et al.
Publicado: (2017)

Re-Understanding the Mechanisms of Action of the Anti-Mycobacterial Drug Bedaquiline
por: Sarathy, Jickky Palmae, et al.
Publicado: (2019)

Adverse effects of bedaquiline in patients with extensively drug-resistant tuberculosis
por: Gaida, Razia, et al.
Publicado: (2020)

Addressing bedaquiline treatment interruptions in the treatment of drug-resistant TB
por: Kambili, C., et al.
Publicado: (2022)

Long-term impact of the adoption of bedaquiline-containing regimens on the burden of drug-resistant tuberculosis in China
por: Agnarson, Abela Mpobela, et al.
Publicado: (2020)

Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries
por: Lu, Xiaoyan, et al.
Publicado: (2017)

Crystal structures of salts of bedaquiline
por: Okezue, Mercy, et al.
Publicado: (2020)

Improved Synthesis and Isolation of Bedaquiline
por: Lubanyana, Hlengekile, et al.
Publicado: (2020)

Salts and Polymorph Screens for Bedaquiline
por: Okezue, Mercy, et al.
Publicado: (2021)

Validation of Bedaquiline Phenotypic Drug Susceptibility Testing Methods and Breakpoints: a Multilaboratory, Multicountry Study
por: Kaniga, Koné, et al.
Publicado: (2020)

Bedaquiline: A new drug approved for treatment of multidrug-resistant tuberculosis
por: Deoghare, Shashank
Publicado: (2013)

Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients
por: Nimmo, Camus, et al.
Publicado: (2020)

Antituberculosis Drug Interactions with Membranes: A Biophysical Approach Applied to Bedaquiline
por: Pinheiro, Marina, et al.
Publicado: (2019)

Primary Bedaquiline Resistance Among Cases of Drug-Resistant Tuberculosis in Taiwan
por: Wu, Sheng-Han, et al.
Publicado: (2021)

Preparation Strategies of the Anti-Mycobacterial Drug Bedaquiline for Intrapulmonary Routes of Administration
por: Maloney, Sara E., et al.
Publicado: (2023)

India should speed up access to bedaquiline-based all-oral regimens, not procrastinate further
por: Udwadia, Zarir F, et al.
Publicado: (2021)

Bedaquiline Drug Resistance Emergence Assessment in Multidrug-Resistant Tuberculosis (MDR-TB): a 5-Year Prospective In Vitro Surveillance Study of Bedaquiline and Other Second-Line Drug Susceptibility Testing in MDR-TB Isolates
por: Kaniga, Koné, et al.
Publicado: (2022)

Advances of new drugs bedaquiline and delamanid in the treatment of multi-drug resistant tuberculosis in children
por: Zhu, Hanzhao, et al.
Publicado: (2023)

Treatment Outcomes of Patients with Multidrug-Resistant Tuberculosis: Concern to Bedaquiline: Authors’ Reply
por: Kang, Yewon, et al.
Publicado: (2022)

Acquired Resistance of Mycobacterium tuberculosis to Bedaquiline
por: Andries, Koen, et al.
Publicado: (2014)

Correction to “Improved Synthesis and Isolation of Bedaquiline”
por: Lubanyana, Hlengekile, et al.
Publicado: (2020)

Public investments in the clinical development of bedaquiline
por: Gotham, Dzintars, et al.
Publicado: (2020)

Daily Dosing for Bedaquiline in Patients with Tuberculosis
por: Salinger, David H., et al.
Publicado: (2019)

Acquired bedaquiline resistance in Karakalpakstan, Uzbekistan
por: Nair, P., et al.
Publicado: (2022)

Primary bedaquiline resistance in Karakalpakstan, Uzbekistan
por: Moe, S., et al.
Publicado: (2023)

New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid
por: Brigden, Grania, et al.
Publicado: (2015)

First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline
por: Tadolini, Marina, et al.
Publicado: (2016)

Structure-activity relationships for unit C pyridyl analogues of the tuberculosis drug bedaquiline
por: Blaser, Adrian, et al.
Publicado: (2019)

Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts
por: Oelofse, S., et al.
Publicado: (2021)

Impact of Rv0678 mutations on patients with drug-resistant TB treated with bedaquiline
por: Kaniga, K., et al.
Publicado: (2022)

Time to Culture Conversion of Bedaquiline and High-Dose Isoniazid for Drug-Resistant Tuberculosis
por: Walsh, Kathleen F, et al.
Publicado: (2022)

Separation and Characterization of Novel Degradation and Process Related Impurities of Bedaquiline Bulk Drug
por: Vanavi, Pragati J, et al.
Publicado: (2021)

Bedaquiline, Delamanid, Linezolid, and Clofazimine for Treatment of Pre-extensively Drug-Resistant Tuberculosis
por: Padmapriyadarsini, Chandrasekaran, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_u34jc00rpbv2iu4qr5q0oqk19k